These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35725652)

  • 1. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial.
    Izadi M; Sadr Hashemi Nejad A; Moazenchi M; Masoumi S; Rabbani A; Kompani F; Hedayati Asl AA; Abbasi Kakroodi F; Jaroughi N; Mohseni Meybodi MA; Setoodeh A; Abbasi F; Hosseini SE; Moeini Nia F; Salman Yazdi R; Navabi R; Hajizadeh-Saffar E; Baharvand H
    Stem Cell Res Ther; 2022 Jun; 13(1):264. PubMed ID: 35725652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes.
    Zhang W; Ling Q; Wang B; Wang K; Pang J; Lu J; Bi Y; Zhu D
    Stem Cell Res Ther; 2022 Aug; 13(1):406. PubMed ID: 35941696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study.
    Lu J; Shen SM; Ling Q; Wang B; Li LR; Zhang W; Qu DD; Bi Y; Zhu DL
    Stem Cell Res Ther; 2021 Jun; 12(1):340. PubMed ID: 34112266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties.
    Yaochite JN; de Lima KW; Caliari-Oliveira C; Palma PV; Couri CE; Simões BP; Covas DT; Voltarelli JC; Oliveira MC; Donadi EA; Malmegrim KC
    Stem Cell Res Ther; 2016 Jan; 7():14. PubMed ID: 26781648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
    Hare JM; Fishman JE; Gerstenblith G; DiFede Velazquez DL; Zambrano JP; Suncion VY; Tracy M; Ghersin E; Johnston PV; Brinker JA; Breton E; Davis-Sproul J; Schulman IH; Byrnes J; Mendizabal AM; Lowery MH; Rouy D; Altman P; Wong Po Foo C; Ruiz P; Amador A; Da Silva J; McNiece IK; Heldman AW; George R; Lardo A
    JAMA; 2012 Dec; 308(22):2369-79. PubMed ID: 23117550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial.
    Zang L; Li Y; Hao H; Liu J; Cheng Y; Li B; Yin Y; Zhang Q; Gao F; Wang H; Gu S; Li J; Lin F; Zhu Y; Tian G; Chen Y; Gu W; Du J; Chen K; Guo Q; Yang G; Pei Y; Yan W; Wang X; Meng J; Zhang S; Ba J; Lyu Z; Dou J; Han W; Mu Y
    Stem Cell Res Ther; 2022 May; 13(1):180. PubMed ID: 35505375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data.
    He J; Kong D; Yang Z; Guo R; Amponsah AE; Feng B; Zhang X; Zhang W; Liu A; Ma J; O'Brien T; Cui H
    PLoS One; 2021; 16(3):e0247662. PubMed ID: 33705413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus.
    Liu X; Zheng P; Wang X; Dai G; Cheng H; Zhang Z; Hua R; Niu X; Shi J; An Y
    Stem Cell Res Ther; 2014 Apr; 5(2):57. PubMed ID: 24759263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
    Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
    Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
    Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
    Trials; 2019 May; 20(1):263. PubMed ID: 31072380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
    Heldman AW; DiFede DL; Fishman JE; Zambrano JP; Trachtenberg BH; Karantalis V; Mushtaq M; Williams AR; Suncion VY; McNiece IK; Ghersin E; Soto V; Lopera G; Miki R; Willens H; Hendel R; Mitrani R; Pattany P; Feigenbaum G; Oskouei B; Byrnes J; Lowery MH; Sierra J; Pujol MV; Delgado C; Gonzalez PJ; Rodriguez JE; Bagno LL; Rouy D; Altman P; Foo CW; da Silva J; Anderson E; Schwarz R; Mendizabal A; Hare JM
    JAMA; 2014 Jan; 311(1):62-73. PubMed ID: 24247587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Karyana M; Djaharuddin I; Rif'ati L; Arif M; Choi MK; Angginy N; Yoon A; Han J; Josh F; Arlinda D; Narulita A; Muchtar F; Bakri RA; Irmansyah S
    Stem Cell Res Ther; 2022 Apr; 13(1):134. PubMed ID: 35365239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
    Couri CE; Oliveira MC; Stracieri AB; Moraes DA; Pieroni F; Barros GM; Madeira MI; Malmegrim KC; Foss-Freitas MC; Simões BP; Martinez EZ; Foss MC; Burt RK; Voltarelli JC
    JAMA; 2009 Apr; 301(15):1573-9. PubMed ID: 19366777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study.
    Bhansali S; Dutta P; Kumar V; Yadav MK; Jain A; Mudaliar S; Bhansali S; Sharma RR; Jha V; Marwaha N; Khandelwal N; Srinivasan A; Sachdeva N; Hawkins M; Bhansali A
    Stem Cells Dev; 2017 Apr; 26(7):471-481. PubMed ID: 28006991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II).
    Lamo-Espinosa JM; Mora G; Blanco JF; Granero-Moltó F; Nuñez-Córdoba JM; Sánchez-Echenique C; Bondía JM; Aquerreta JD; Andreu EJ; Ornilla E; Villarón EM; Valentí-Azcárate A; Sánchez-Guijo F; Del Cañizo MC; Valentí-Nin JR; Prósper F
    J Transl Med; 2016 Aug; 14(1):246. PubMed ID: 27565858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the route of administration and efficacy of adipose tissue-derived mesenchymal stem cells and conditioned medium in type 1 diabetic mice.
    Hashemi SM; Hassan ZM; Hossein-Khannazer N; Pourfathollah AA; Soudi S
    Inflammopharmacology; 2020 Apr; 28(2):585-601. PubMed ID: 31741175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
    Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
    Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
    Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.